Oxiracetam in the treatment of multi-infarct dementia

Bernard Baumel, Larry Eisner, Michael Karukin, Rosemary Macnamara, Richard J. Katz, Joseph Deveaugh-Geiss

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

1. 1. Initial clinical trials in approximately 200 patients with dementias of diverse etiology suggested that oxiracetam, a structural analogue of the nootropic piracetam, was of some benefit in the treatment of cognitive dysfunction. 2. 2. Because previous studies had not specifically examined the effects of oxiracetam upon dementias of vascular origin, the present study evaluated the therapeutic efficacy and safety of oxiracetam in the treatment of symptoms of multi-infarct dementia (MID) of Bild to moderate severity. 3. 3. Incremental doses of up to 1200 mg oxiracetam daily were tested in a dose-range finding design in a group of patients with clinically and neuropsychologically confirmed MID. 4. 4. Based on improvement in global evaluations of clinical change, our analysis suggests that the drug may be of some benefit in MID.

Original languageEnglish (US)
Pages (from-to)673-682
Number of pages10
JournalProgress in Neuropsychopharmacology and Biological Psychiatry
Volume13
Issue number5
DOIs
StatePublished - 1989
Externally publishedYes

Fingerprint

Multi-Infarct Dementia
Piracetam
Nootropic Agents
Vascular Dementia
Therapeutics
Dementia
Clinical Trials
Safety
oxiracetam
Pharmaceutical Preparations

Keywords

  • dementia
  • multi-infarct dementia
  • nootropic
  • oxiracetam

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Cite this

Oxiracetam in the treatment of multi-infarct dementia. / Baumel, Bernard; Eisner, Larry; Karukin, Michael; Macnamara, Rosemary; Katz, Richard J.; Deveaugh-Geiss, Joseph.

In: Progress in Neuropsychopharmacology and Biological Psychiatry, Vol. 13, No. 5, 1989, p. 673-682.

Research output: Contribution to journalArticle

Baumel, Bernard ; Eisner, Larry ; Karukin, Michael ; Macnamara, Rosemary ; Katz, Richard J. ; Deveaugh-Geiss, Joseph. / Oxiracetam in the treatment of multi-infarct dementia. In: Progress in Neuropsychopharmacology and Biological Psychiatry. 1989 ; Vol. 13, No. 5. pp. 673-682.
@article{3f6ac2f1bb3448b49fff26880c33518a,
title = "Oxiracetam in the treatment of multi-infarct dementia",
abstract = "1. 1. Initial clinical trials in approximately 200 patients with dementias of diverse etiology suggested that oxiracetam, a structural analogue of the nootropic piracetam, was of some benefit in the treatment of cognitive dysfunction. 2. 2. Because previous studies had not specifically examined the effects of oxiracetam upon dementias of vascular origin, the present study evaluated the therapeutic efficacy and safety of oxiracetam in the treatment of symptoms of multi-infarct dementia (MID) of Bild to moderate severity. 3. 3. Incremental doses of up to 1200 mg oxiracetam daily were tested in a dose-range finding design in a group of patients with clinically and neuropsychologically confirmed MID. 4. 4. Based on improvement in global evaluations of clinical change, our analysis suggests that the drug may be of some benefit in MID.",
keywords = "dementia, multi-infarct dementia, nootropic, oxiracetam",
author = "Bernard Baumel and Larry Eisner and Michael Karukin and Rosemary Macnamara and Katz, {Richard J.} and Joseph Deveaugh-Geiss",
year = "1989",
doi = "10.1016/0278-5846(89)90054-7",
language = "English (US)",
volume = "13",
pages = "673--682",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Oxiracetam in the treatment of multi-infarct dementia

AU - Baumel, Bernard

AU - Eisner, Larry

AU - Karukin, Michael

AU - Macnamara, Rosemary

AU - Katz, Richard J.

AU - Deveaugh-Geiss, Joseph

PY - 1989

Y1 - 1989

N2 - 1. 1. Initial clinical trials in approximately 200 patients with dementias of diverse etiology suggested that oxiracetam, a structural analogue of the nootropic piracetam, was of some benefit in the treatment of cognitive dysfunction. 2. 2. Because previous studies had not specifically examined the effects of oxiracetam upon dementias of vascular origin, the present study evaluated the therapeutic efficacy and safety of oxiracetam in the treatment of symptoms of multi-infarct dementia (MID) of Bild to moderate severity. 3. 3. Incremental doses of up to 1200 mg oxiracetam daily were tested in a dose-range finding design in a group of patients with clinically and neuropsychologically confirmed MID. 4. 4. Based on improvement in global evaluations of clinical change, our analysis suggests that the drug may be of some benefit in MID.

AB - 1. 1. Initial clinical trials in approximately 200 patients with dementias of diverse etiology suggested that oxiracetam, a structural analogue of the nootropic piracetam, was of some benefit in the treatment of cognitive dysfunction. 2. 2. Because previous studies had not specifically examined the effects of oxiracetam upon dementias of vascular origin, the present study evaluated the therapeutic efficacy and safety of oxiracetam in the treatment of symptoms of multi-infarct dementia (MID) of Bild to moderate severity. 3. 3. Incremental doses of up to 1200 mg oxiracetam daily were tested in a dose-range finding design in a group of patients with clinically and neuropsychologically confirmed MID. 4. 4. Based on improvement in global evaluations of clinical change, our analysis suggests that the drug may be of some benefit in MID.

KW - dementia

KW - multi-infarct dementia

KW - nootropic

KW - oxiracetam

UR - http://www.scopus.com/inward/record.url?scp=0024455491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024455491&partnerID=8YFLogxK

U2 - 10.1016/0278-5846(89)90054-7

DO - 10.1016/0278-5846(89)90054-7

M3 - Article

VL - 13

SP - 673

EP - 682

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 5

ER -